ELISA

A Phase 2 Study of Elranatamab in Combination With Isatuximab (ELISA) in Relapsed and Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
30 patients (estimated)
Tags
T Cell Engager (TCE), Bispecific Antibody, B-Cell Maturation Antigen (BCMA)
Trial Type
Treatment
Last Update
SparkCures ID
2248
NCT Identifier
NCT06832865

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.